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Epidemiology, Erasmus Medical Center, Rotterdam, The NetherlandsA B S T R A C TObjective: The aim of the study was to evaluate the cost-effectiveness
of a cognitive-behavioral group training compared with a wait-list
control for patients with unexplained physical symptoms (UPS).
Methods: A probabilistic decision-analytic Markov model was devel-
oped with three health states (poor health, average health, and death)
based on a cutoff score of the Physical Component Summary of the
short-form 36 health survey. To assess the cost-effectiveness in terms
of cost per quality-adjusted life-year (QALY), a societal perspective
was adopted. The model consisted of cycles of 3 months and a time
horizon of 4 years. Data for the model were derived from a random-
ized controlled trial, in which 162 patients with UPS were randomized
either to cognitive-behavioral group training or to the wait-list con-
trol. Data were assessed at baseline and after the training of 3 months
or after a wait-list period of 3 months. In addition, the training groupee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2015.03.1791
r@erasmusmc.nl.
ndence to:Martijn S. Visser, Postbus 2040, 3000 CAwas followed in an uncontrolled phase and assessed at 3 months and
1 year after the training. Results: After 4 years, the group training was
in terms of cost-effectiveness “dominant” compared with the wait-list
control; there was a positive effect of 0.06 QALYs and a €828 reduction
in costs. The cost-effectiveness improved with a longer time horizon.
A threshold of €30,000/QALY was passed after 18 months. The group
training was cost saving after 33 months. Conclusions: Cognitive-
behavioral group training is a cost-effective treatment compared with
the wait-list control for patients with UPS.
Keywords: cost-effectiveness, Unexplained physical symptoms,
quality-adjusted life-year.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Background
Unexplained physical symptoms (UPS) are physical symptoms
that cannot be fully explained on the basis of a known medical
condition. These symptoms can be classiﬁed as a Diagnostic and
Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV)
somatoform disorder if they 1) are not intentionally produced
or feigned, 2) cause clinically signiﬁcant distress or impairment in
functioning, 3) persist for at least 6 months, and 4) are not better
accounted for by other DSM-IV classiﬁcations. Somatoform dis-
orders are common in primary care [1,2]. Their prevalence ranges
from 4% (without the prevalence of undifferentiated somatoform
disorder and body dysmorphic disorder in a 18–80-year old
population) [3] to 16% (without the prevalence of somatoform
disorder not otherwise speciﬁed in a 25–80-year old population)
[4]. By deﬁnition, somatoform disorders are accompanied by high
levels of psychosocial distress and/or impairment, resulting in
lost labor-force and household productivity [5] and in a high use
of health care services [6,7]. The high prevalence rate of UPS
combined with its high costs make it not only a considerableburden for patients but also an economic burden for society
[5,6,8].
Research indicates that cognitive-behavioral therapy is the
most effective therapy for UPS [9,10], but research into the cost-
effectiveness of this therapy is scarce and has methodological
limitations. A recent systematic literature review [11] identiﬁed
eight economic evaluations of treatments for UPS, of which only
two investigated the cost-effectiveness by explicitly combining
differences in costs with differences in effects into incremental
cost-effectiveness ratios (ICERs) (the ratio of additional costs and
additional effects). Even these studies, however, did not use a
state-of-the-art cost-effectiveness research design, which makes
meta-syntheses difﬁcult, because they did not include costs due
to work-related productivity losses, applied a time horizon
limited to 1 year [12] or to 3 months [13], and mainly used
disease-speciﬁc measures of effectiveness such as “cost per unit
reduction in Health Anxiety Inventory score” [12] and “cost per
additional successfully treated patient” rather than quality-
adjusted life-years (QALYs) [13]. The use of such speciﬁc effect
measures complicates comparisons of cost-effectiveness ratios ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Rotterdam, The Netherlands.
Table 1 – Baseline characteristics.
Characteristic Group
training
(n ¼ 84)
Wait-list
control
(n ¼ 78)
Age (y), mean 46 44
Sex: female (%) 80 82
Physical Component Summary
(PCS) score, mean
29.34 29.05
Mental Component Summary
(MCS) score, mean
43.68 46.72
Duration of UPS (y), median 8 9.5
Classiﬁcation of comorbid DSM-IV axis I disorders measured by
SCID-I/P
Mood disorder (lifetime) 13 (40) 11 (30)
Anxiety disorder (lifetime) 20 (36) 27 (41)
Substance-related disorder
(lifetime)
1 (12) 0 (6)
Eating disorder (lifetime) 1 (4) 0 (2)
Psychotic disorder (lifetime) 0 (0) 0 (1)
Somatization disorder 14 10
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7 571different treatments not only within the same disease but also
between different diseases, such as comparing the cost-
effectiveness ratios of treatments for UPS with those of treat-
ments for diabetes. When these comparisons of cost-
effectiveness ratios are favorable to treatments for UPS, one
would have a strong argument to reimburse treatment of UPS
similar to diseases with a known medical diagnosis. Such
comparisons require the use of generic effect variables such as
costs per QALY, which is the preferred outcome in health
economics [14].
In health economics, one tries to incorporate all costs and
effects, even if the costs and effects occur in the future [14],
complemented with implementation costs. Future costs and
effects are, for instance, important if one claims that the initial
investment in the treatment is offset by future saving in health
care costs elsewhere and can be modeled with a Markov model
[13]. Uncertainty in the parameter values can be modeled with
probabilistic sensitivity analysis [15].
The purpose of this study was to evaluate the cost-
effectiveness of a cognitive-behavioral group training compared
with a wait-list control for patients with UPS using a probabilistic
Markov model.Hypochondriasis 1 1
Adjustment disorder 2 2
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition); SCID-I/P, Structured Clinical Interview for DSM-IV Axis I
Disorders/Patient edition.Methods
Design
The data for the study emerged from a 3-month randomized
controlled trial combined with an uncontrolled 1-year follow-up
investigating the effectiveness of cognitive-behavioral group
training for patients with UPS [16]. In the trial, after completing
the baseline measurement (T0), patients were randomized either
to the group training (training group 1) or to a wait-list control
group. The treatment effect was measured 3 months later,
corresponding with the length of the training (T1).
After T1, patients on the wait-list control also attended the
training (training group 2). In training group 2, the T1 was the
baseline score (T0) and the training group 2 followed the same
procedure as did training group 1. In the uncontrolled follow-up,
the outcome for both training groups was measured at 3 months
after the end of the training (T2) and once again at 1 year after the
end of the training (T3). The study was approved by the Erasmus
Medical Research Ethics Committee, and registered in the Dutch
Trial Register (NTR 1609) [17]. A detailed description of the study
protocol has been published elsewhere [18].
Participants
Participants were recruited in outpatient clinics at general hos-
pitals, and by Riagg Rijnmond, a secondary community mental
health service in the Rotterdam area in The Netherlands. General
practitioners and specialists were asked to refer patients aged
between 18 and 65 years whose physical symptoms, according to
their clinical judgment, could not be explained on the basis of a
known medical condition. Patients were included if they signed
the informed consent and if their UPS fulﬁlled the DSM-IV criteria
for an undifferentiated somatoform disorder or a chronic pain
disorder using the Structured Clinical Interview for DSM-IV Axis I
Disorders/Patient edition [19]. Patients were excluded if poor lan-
guage skills or handicaps, such as cognitive impairment, pre-
vented them from understanding the cognitive-behavioral group
training. Table 1 presents the patients’ baseline characteristics.
Cognitive-Behavioral Group Training
The cognitive-behavioral group training is called “Coping with
the consequences of unexplained physical symptoms.” Thisweekly 2-hour manual-based [20] training was held over a 3-
month period. The group training started with a minimum of 5
and a maximum of 10 patients. Patients assigned to the group
training attended, on average, 11 of the 13 sessions, with a
minimum of 6. The aim of the group training was to improve
health-related quality of life. Corresponding to this aim, the
primary outcome measures in the randomized controlled trial
were the two component summaries of the 36-item Medical
Outcomes Study short-form health survey (SF-36) [21,22]: Physical
Component Summary (PCS) and Mental Component Summary.
More details of the group training [18,23,24] as well as its
effectiveness [16] have been published elsewhere.Cost-Effectiveness
The randomized controlled trial provided empirical data of the
costs and effects of the group training and the wait-list control. The
uncontrolled follow-up extended the empirical data by 1 year by
following both training groups 1 and 2. It is to be expected, however,
that the effect will sustain longer than these periods. We therefore
developed a Markov cohort model [15] in which we simulated a
cohort of patients that moved through health states over time.
PCS was used as the primary outcome measure [16]. Patients
reported the quality of life in the physical domain as most
burdensome, compared with that in the mental domain, and
PCS had been shown to be a sensitive parameter for the effects of
the group training. The Markov cohort model deﬁned three ﬁxed
mutually exclusive health states: average health (AH), poor health
(PH), and death (Fig. 1). To deﬁne AH and PH, a cutoff score of 40
on the PCS was used because the score of 40 was in the middle
between the scores of the general population (mean 50  10) and
the scores of the patients included in this study (mean ¼ 29  9).
AH represented patients with scores higher than 40 on the PCS,
and PH represented patients with scores lower than 40 on the PCS.
The variation over time in the effects and in the costs within
the health states AH and PH was nonsigniﬁcant and assumed to
be constant over time. The length of the Markov cycles was
chosen to be 3 months, so that the 3 months of the training could
Fig. 1 – State transition diagram of the Markov model for
unexplained physical symptoms.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7572be accommodated in just one cycle. To acknowledge the uncer-
tainty of the long-term effects, we used a time horizon of 4 years
and not an inﬁnite time horizon as baseline scenario. Although
an inﬁnite time horizon would align with health-economic
guidelines [14], it would also assume that the effects will sustain
well beyond 4 years. This was considered an unrealistic assump-
tion, given that we had only 3-month data to compare the effects
of the group training with those of the wait-list control. Because
we did not know how long effects might sustain, we were also
interested in the minimal duration of sustained effect needed to
show acceptable cost-effectiveness. If the time horizon would be
short, the assumption of sustaining the effect would be less
inﬂuential in considering the validity of the cost-effectiveness
estimated. Both the mean age of the simulated patient cohort in
the model (45 years) and the distribution of patients over health
states (AH ¼ 11%; PH ¼ 89%) at the start of the model were
derived from the trial data at baseline (T0). Costs per patient will
depend on the number of participants per training: more partic-
ipants would mean lower cost per patient, under the assumption
of similar effects. The average number of participants per train-
ing in the model was six patients.
Transition Probabilities
To allow transitions between health states (improve or relapse),
transition probabilities were computed on the basis of study data
(Table 2). For patients on the wait-list control, data from only T0
and T1 were available. After T1, the transition probabilities for
the wait-list control condition had to be assumed. In the wait-list
control group, nine patients were in health state AH at T0, and
none of them deteriorated (relapsed) to the health state PH in the
ﬁrst cycle. Other patients on the wait-list control were in health
state PH at T0, and two patients improved from PH to AH. Given
the chronic character of UPS (in our sample, the median duration
of UPS was 9 years), a zero relapse chance for patients on the
wait-list control in the health state AH did not seem to be a
reasonable assumption. In fact, given the median duration, it
might be more likely that relapse and improvement in the wait-
list control condition were in balance. We therefore assumed
“transition balance” after the ﬁrst cycle of 3 months, in which the
probabilities were estimated in such a way that the number of
transitions between the health states in the wait-list control
condition was equal. The relapse in the ﬁrst cycle was in line with
the data, so no patients deteriorated in this cycle.
For the training group, the transition probabilities for the ﬁrst
cycle were estimated using the T0-T1 data of the training group 1
(the original “experimental” training group) combined with the
T0-T1 data of training group 2 (the original wait-list control
group). The transition probabilities after attending the training
were determined using data T1 through T3, and assumed to be
constant after T3.
Mortality ﬁgures were derived from the Dutch standard life
tables in 2010 provided by Statistics Netherlands CBS [25]. Itincluded an average death risk depending on age for both men
and women but not for patients with UPS speciﬁcally. We
assumed the same mortality for patients with AH and PH.
Costs
The costs of the group training were calculated on the basis of a
local cost study (see Table 3), and included the estimation of the
volume and cost prices of personnel [26], overhead, material,
housing, training and retraining of personnel, recruitment, and
travel. Productivity cost related to the time patients needed to
follow the group training was not measured because only 45% of
the patients were working, of whom 48% worked 24 hours or less.
Furthermore, patients had the opportunity to follow the training
outside working hours. Note that we did measure the productiv-
ity cost related to the illness but, as explained above, not the
productivity costs associated with the training.
To estimate all medical costs other than the group training,
with the exclusion of the trial costs, we used the 2002 version of
the Trimbos/iMTA Questionnaire for Costs associated with Psychiatric
Illness (TiC-P), a self-report questionnaire for assessing health
care–related and work-related costs of illness. The TiC-P has 29
questions and semi-ﬁxed-response alternatives [27,28]. The ﬁrst
part of the TiC-P measures health care–related costs incurred
through the use of health care services and medications over the
past 4 weeks. The second part of the TiC-P, which is based on the
short form of the Health and Labour Questionnaire, measures
work-related costs over the past 2 weeks caused by absenteeism
(the absence from work), presenteeism (a reduced efﬁciency at
work), and substitution of domestic tasks.
The health states were ﬁxed and assumed to be constant over
time. Therefore, an average of the cost scores was used per cycle
for the health states. This assumption was supported by the
constant ﬂat distribution of total costs over time, which can be
observed in Table 4. Costs were discounted at 4%, consistent with
Dutch guidelines of pharmacoeconomical evaluations, and rep-
resented 2011 cost prices [29].QALYs
The effects were expressed in terms of QALYs. The quality-of-life
weights needed to estimate the QALYs (the so-called utilities) were
extracted from the SF-36 [21]. Eleven of the 36 items of this self-
report questionnaire are converted into six dimensions (six-dimen-
sional health state short form [derived from SF-36]): physical
functioning, role limitations, social functioning, pain, mental health,
and vitality [30]. Like costs, utilities were assumed to be constant
over time and therefore an average of the utility scores was used per
cycle for the health states. This assumption was supported by the
constant distribution over time, which can be observed in Table 5.
Effects were discounted at a rate of 1.5% per year, consistent with
Dutch guidelines of pharmacoeconomical evaluations [29].
Analysis
Because this study involved synthesizing data from a number of
sources with different forms of sampling errors and with differ-
ent assumptions, it is important to assess the uncertainties in the
model in a multivariable way and under varying assumptions.
Probabilistic sensitivity analysis of the uncertainty of parameters
(i.e., the uncertainty that relates to sampling error) was under-
taken with second-order Monte Carlo simulation. The parameters
included transition probabilities, QALYs, and costs. Because the
costs were skewed, gamma distributions were used for the costs
in the model. For the transition probabilities and QALYs,
beta distributions were used. Ten thousand simulations were
Table 2 – Transition probabilities extracted from the trial.
Transition T0-4T1 T1-4T2 T2-4T3
Mean SE N Mean SE N Mean SE N
Group training*
Improve (from PH to AH) 0.18 0.041 16 0.11 0.037 8 0.04 0.023 7
Stay in PH 0.82† 71 0.89† 64 0.96† 60
Relapse (from AH to PH) 0.17 0.103 2 0.32 0.091 8 0.14 0.066 10
Stay in AH 0.83† 10 0.68† 17 0.86† 17
Wait-list control
Improve (from PH to AH)‡ 0.04 0.024 2
Stay in PH‡ 0.96† 55
Relapse (from AH to PH) 0.0 0.0 0 0.29§ 0.132
Stay in AH 1.0 9 0.71†,§
AH, average health; PH, poor health.
* In the calculations, training groups 1 and 2 were used.
† This is the inverse of a transition and has the same standard error.
‡ Transitions were measured only in the ﬁrst cycle and extrapolated to the subsequent cycles.
§ The mean was based on “transition balance” and extrapolated to the subsequent cycles.
Table 3 – Costs per training.
Category Cost (€)
Personnel 7,048
Overhead 2,502
Material 131
Housing 1,050
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7 573conducted, in which parameter values for transition probabilities,
costs, and QALYs were randomly sampled from their distribution.
This resulted in 10,000 unique sets of parameters, which were
used in the model to calculate the expected costs and QALYs of a
cohort of 1000 patients in the training condition and a cohort of
1000 patients on a “4-year wait-list control” condition. The
resulting costs and effects were combined to calculate the ICER.
If a trade-off needs to be made between costs and effects, a
threshold is needed; that is, how much is society willing to pay
for additional health? The societal willingness-to-pay (WTP) level
was set at €30,000 per gained QALY, which roughly reﬂects an
accepted WTP level in The Netherlands [31].
Furthermore, a cost-effectiveness acceptability curve (CEAC) was
created. A CEAC indicates the probability that the intervention
under evaluation will be cost-effective at different values of WTP
for a QALY. By deﬁnition, a CEAC crosses the y-axis at the probability
that the intervention is cost neutral: the WTP is then zero [32].
Sensitivity Analysis
The societal perspective adopted in this article is consistent with the
methods guidelines for economic evaluations in The Netherlands. In
many countries, however, the advised perspective is more restric-
tive, focusing on health care costs. To allow for international
comparisons, we also presented an analysis considering health care
costs only, and thus excluding productivity costs.
In addition, to get more insight into the development of cost-
effectiveness over time, we plotted the ICER after each cycle. As
described before, the effects of the training on training group 2 (the
original wait-list control group) were combined with those on train-
ing group 1. One could argue that the new T0-T1 data may not
represent the effect on which the randomized controlled trial was
based (for instance, because the waiting time also had an effect).
Therefore, we tested the accuracy of combining the data in a
sensitivity analysis by using data only from training group 1, and
plotted the ICER of training group 1. Furthermore, an analysis was
done for a 10-year time horizon, to look beyond the 4-year time
horizon.Training and retraining* 20
Recruitment 15
Travel 775
Total cost 11,541
Total cost per patient 1,924
* Average per training.Results
The mean 4-year costs and health outcomes are presented in
Table 6. The table shows that the training group had lower mean
costs than did the wait-list control group, suggesting that costs oftraining were offset with savings elsewhere. The training group
had a higher number of mean QALYs than did the wait-list
control group, suggesting better outcome for patients after the
training. Thus, after 4 years, the training showed better effects
against lower costs in comparison to the wait-list control, making
it a dominant strategy.
The impact of parameters’ uncertainty on the ICER is shown
in Figure 2, in which results of 10,000 probabilistic simulations
are plotted in a scatterplot. The scatterplot shows the differences
in costs and QALYs per simulation per patient between the group
training and the wait-list control. When ICERs are in the bottom
right quarter of the scatterplot, the training is dominant, that is,
cost saving with QALY improvement. When ICERs are in the top
left quarter, the training costs more, and does not improve
health. For the top right quarter, a trade-off should be made
between costs and effects. Around 64% of the simulations ended
up in the bottom right quarter, which means cost saving and
QALY improvement. Approximately 86% of the simulations were
below the threshold of €30,000 per gained QALY, which means
that costs for improvement were within the borders that society
is willing to pay for additional health (WTP). The increase in
QALYs seemed to be modest, smaller than 0.18 over 4 years.
Because almost all simulations ended up at the right side of the
y-axis, however, improvement appeared with high certainty.
Figure 3 indicates the probability that the cognitive-behavioral
group training will be cost-effective at different values of WTP for
a QALY. The CEAC for the group training crossed the y-axis at the
probability of 0.65, which means that the group training was cost
saving (WTP ¼ 0) in approximately 65% of the simulations. This
Table 4 – Health care–related and work-related costs per cycle.
Costs (€) T1* T2 T3 Average†,‡
PH
(N ¼ 133)
AH
(N ¼ 35)
PH
(N ¼ 78)
AH
(N ¼ 28)
PH
(N ¼ 72)
AH
(N ¼ 27)
PH
(N ¼ 283)
AH
(N ¼ 90)
Health care–related costs
Medication costs 56 17 65 18 58 26 59 20
Other medical costs 1,181 677 1709 640 1827 571 1491 634
General practitioner 130 89 112 51 109 56 120 (4.13) 67 (2.31)
Therapist (Riagg) 256 296 258 206 144 43 228 (1.29) 192 (1.08)
Medical specialist 159 90 143 35 205 153 166 (2.23) 92 (1.23)
Paramedic 193 66 201 108 221 108 202 (5.42) 92 (2.46)
Hospitalization days 194 0 745 69 934 0 534 (1.02) 22 (0.04)
Work-related costs
Absenteeism 343 18 184 104 341 – 298 (10.26) 40 (1.37)
Presenteeism 188 23 97 – 50 9 128 (9.26) 11 (8.10)
Substitution of
domestic tasks
498 102 492 43 586 12 519 (35.23) 57 (4.19)
Total costs 2266 837 2547 805 2861 619 2495 762
AH, average health; PH, poor health.
* In the calculations, the T1 of training group 1, “new T1” of training group 2, and T1 of wait-list control group were used.
† For the model, the average values were used because differences between measurements were nonsigniﬁcant.
‡ Average volumes of service use and lost to work time is placed within parentheses.
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the group training. If society is willing to pay €30,000/QALY, the
chance that the group training will be a more cost-effective
option than a wait-list control was 80%. Stated differently, if
society is willing to pay €30,000/QALY, the chance that the wait-
list control will be the most cost-effective option was only 20%.
Sensitivity analysis concerning adoption to the health care
perspective resulted in higher incremental costs after 4 years
(Table 6), resulting in a low positive ICER.
Figure 4 reﬂects the uncertainty of the ICERs over time, and
also includes the ICERs when excluding the effect data of training
group 2. After 18 months (six cycles), the cost of a gained QALY
because of the group training was less than €30,000. After 30
months (10 cycles), the cost of a gained QALY because of the
group training was zero. When using data only from training
group 1, comparable results were found. When increasing the
time horizon to a period of 10 years (not shown in ﬁgure), the
group training was in terms of cost-effectiveness “dominant”
compared with the wait-list control and there was a positive
effect of 0.13 QALYs and a €3777 reduction in costs.Discussion
Principal Findings
We estimated the cost-effectiveness of cognitive-behavioral
group training for patients with UPS over a 4-year time horizonTable 5 – Utilities.
Health state Baseline T1*
Poor health
Mean (SE) 0.57 (0.007) 0.58 (0.007)
Average health
Mean (SE) 0.69 (0.027) 0.71 (0.015)
SE, standard error.
* In the calculations, the “new T1” of training group 2 was also used.
† For the model, average values were used because differences betweenusing a multivariable probabilistic model. After 4 years, the group
training had a better effect on health-related quality of life and
lower costs from a societal perspective than did the wait-list
control. The group training was a dominant strategy: it was both
more effective and cost saving compared with the wait-list
control. After 30 months, the effect of the cognitive-behavioral
group training was cost saving. If society is willing to pay €30,000
per gained QALY, then the group training was cost-effective after
18 months. This corresponds more or less with the end of the
study period (15 months), which indicates that only a small
amount of extrapolation of costs, effects, and transition data
was needed in the group training before a reasonable cost-
effectiveness was reached. Using a time horizon of 4 years and
assuming no WTP for gained QALYs, the chance that the training
will be cost-effective compared with the wait-list control
was 65%.Our Principal Findings in Relation to the Existing Literature
Our study is one of the few cost-effectiveness studies in patients
with UPS, and the ﬁrst to use a state-of-the-art health economic
model and the preferred outcome in health economics: QALYs.
To our knowledge, only two studies investigated the cost-
effectiveness of treatment for patients with UPS using cost-
effectiveness ratios [11]. Because these studies used a speciﬁc
outcome “cost per unit reduction in Health Anxiety Inventory
score” [12] and “cost per additional successfully treated patient”T2 T3 Average†
0.58 (0.011) 0.58 (0.012) 0.58 (0.004)
0.74 (0.019) 0.73 (0.021) 0.72 (0.010)
measurements were nonsigniﬁcant.
Table 6 – Deterministic discounted costs and health outcomes over 4 y.
Group Costs (€) QALYs ICER (€) Proportion in average health (%)* From a health care perspective
Costs (€) ICER (€)
Group training 32,929 2.35 Dominant 14.0 21.757 8.165/QALY
Wait-list control 33,757 2.29 – 10.8 21.278 –
ICER, incremental cost-effectiveness ratio.
* Percentage of participants in the average health state at 4 y.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7 575[13], the cost-effectiveness of different treatments within UPS is
difﬁcult to compare.
Limitations
In the model, several assumptions were made, of which some
might be considered as in favor of the cost-effectiveness of the
group training, whereas others might be considered as conserva-
tive. First, where most common comparators used in economic
evaluations are categorized as current standard of care or all
relevant treatment alternatives, this economic evaluation is
based on a randomized controlled trial comparing cognitive-
behavioral group training with a wait-list control. For patients
with UPS, several treatments are available in mental health
centers. Patients, however, typically refuse to be referred to these
mental health services [33,34]. For this reason, most patients with
UPS have contacts only within the medical health services.
Therefore, when looking at alternative treatments for this group
of patients with UPS, it is believed that regular GP and other
medical care services are the most relevant comparison because
these patients were not (did not want to be) referred to regular
mental health care services. Second, assuming “transition bal-
ance” in the wait-list control condition after the ﬁrst cycle might
be considered as enhancing cost-effectiveness because then
“spontaneous improvement” was balanced with relapse. The
idea of transition balance comes from the observation that the
UPS of this patient group was chronic: the minimum duration of
UPS was 6 months, and its median duration was 9 years. InFig. 2 – Incremental cost-effecaddition, any favorable effect of the “transition balance assump-
tion” was limited by the time horizon of 4 years and by the
ﬁnding that a satisfying ICER was already reached after 18
months. Another possible alternative for estimating the relapse
rate of the wait list after the ﬁrst cycle was using the relapse rate
found in the group training. This might result, however, in an
overestimation of the relapse rate because the group training has
a higher relapse in time due to the effectiveness in the ﬁrst
period. The latter strategy will provide a too optimistic perspec-
tive and is therefore not used.
Furthermore, merging training groups 1 and 2 might have a
favorable effect on cost-effectiveness. We tested the effect of this
merging in a sensitivity analysis, however, and did not ﬁnd such
a favorable effect.
Moreover, the assumption that none or only a limited amount
of productivity losses occurred as a result of attending the
training might be considered as enhancing cost-effectiveness.
The assumption, however, was supported by the fact that most
patients in our study group had only limited working obligations
and they could attend the training after working hours.
A conservative assumption was the assumption that there
were no differences in terms of mortality. Because the physical
quality of life improved as a result of the training, the life
expectancy might have been increased too.
Finally, the choice of a cutoff score of 40 on the PCS of the
SF-36 might have had an effect on the results. From a clinical
point of view, the use of change scores to deﬁne the health
states might be more appropriate than the use of a cutoff scoretiveness ratio scatte rplot.
Fig. 3 – Cost-effectiveness acceptability curve.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7576because change scores would most likely show more transitions
in health states than a cutoff score at a ﬁxed quality-of-life level
would do.
Theoretical Implications
The aim of the cognitive-behavioral group training is to improve
health-related quality of life of patients with UPS. Because
patients’ quality of life is also negatively related to being older,
being female, having a low level of education, living without a
partner, having one or more comorbid medical conditions [35],
and having one or more comorbid mental disorders [4,36] and
given the fact that patients with UPS seem to run a high risk on
these conditions [4,6,37–42], only a modest increase in quality of
life should be expected. This modest ambition is often accom-
panied by the claim that treatment will reduce health care
consumption [11], which would be beneﬁcial for both patients,
because it might avoid unnecessary medical interventions and
perhaps even iatrogenesis, and society, because it might reduce
health care costs. There is hardly any data to support this claim,
but results of the present study indeed suggested that this
hypothesis might be true: the increase in QALYs was modest,
but the decrease in costs was substantial, which made the
treatment cost saving and preferable over the wait-list control
condition.Fig. 4 – Incremental cost-effectiveClinical and Policy Implication
The clinical and policy implication of this study is that the
favorable results of the cost-effectiveness analysis are an addi-
tional and strong argument to implement and reimburse
cognitive-behavioral therapy for patients with UPS. Such an
implementation will give patients the opportunity to increase
their quality of life and support health care services to provide
the appropriate and most cost-effective treatment for this patient
group. The results are also useful for the payers of health care
services because the results show strong evidence of cost saving
after treatment.Further Research
It is tempting to advice that further research should be a
randomized controlled trial with a longer follow-up in the control
wait-list control condition. In that way, we could test the
assumption of transition balance between health states in the
wait-list control condition. Given that we have already estab-
lished the effectiveness of this treatment, it will be unlikely that
such a design will be approved by any medical ethical research
committee. Instead, it might be more realistic to advise to
conduct a cost-effectiveness study in which different therapies
for patients with UPS are compared head-to-head. Anotherness ratio (ICER) over time.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 5 7 0 – 5 7 7 577advisable investigation might be “implementation research”
because it is likely that treatment compliance of both patients
and health care providers will inﬂuence the cost-effectiveness of
the treatment [42].Conclusions
Our study is one of the few cost-effectiveness studies in patients
with UPS, and the ﬁrst to use a state-of-the-art health economic
model and the preferred outcome in health economics: QALYs.
We showed that the cognitive-behavioral group training is a cost-
effective treatment in patients with UPS compared with a wait-
list control condition.Acknowledgments
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